International Severe Asthma Registry_Hong Kong
ISAR
1 other identifier
observational
500
1 country
1
Brief Summary
To ensure the care of people with severe asthma continues to improve, it is essential we have detailed information on the health and treatment of as many people with the condition as possible. The purpose of the registry is to gather this information and track the progress of patients and how well they are responding to treatment. Medical research using data from the registry will provide a better understanding of asthma and help to develop and improve the care and treatment for patients with asthma. Detailed protocol can be referred to the reference in this trial registration (International severe asthma registry \[ISAR\]: protocol for a global registry).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2025
CompletedFirst Submitted
Initial submission to the registry
March 28, 2026
CompletedFirst Posted
Study publicly available on registry
April 13, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2036
April 13, 2026
March 1, 2026
10.2 years
March 28, 2026
April 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Asthma exacerbations
Number of asthma exacerbations per year
Every year up to 10 years
Secondary Outcomes (1)
Change of medications
every year up to 10 years
Study Arms (1)
Asthma patients
Severe asthma patients
Eligibility Criteria
Patients with severe asthma either 1. on GINA Step 5 therapy 2. Asthma uncontrolled on GINA step 4 therapy (Uncontrolled can be poor symptom control in the past 12 months, persistent airflow limitation in the past 12 months, history of serious exacerbations or history of frequent exacerbations
You may qualify if:
- Patient with severe asthma with age 18 or over will be recruited.
You may not qualify if:
- Patients who cannot provide written consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Chinese University of Hong Kong
Hong Kong, Hong Kong
Related Publications (1)
FitzGerald JM, Tran TN, Alacqua M, Altraja A, Backer V, Bjermer L, Bjornsdottir U, Bourdin A, Brusselle G, Bulathsinhala L, Busby J, Canonica GW, Carter V, Chaudhry I, Cho YS, Christoff G, Cosio BG, Costello RW, Eleangovan N, Gibson PG, Heaney LG, Heffler E, Hew M, Hosseini N, Iwanaga T, Jackson DJ, Jones R, Koh MS, Le T, Lehtimaki L, Ludviksdottir D, Maitland-van der Zee AH, Menzies-Gow A, Murray RB, Papadopoulos NG, Perez-de-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Price CA, Rhee CK, Sadatsafavi M, Tohda Y, Wang E, Wechsler ME, Zangrilli J, Price DB. International severe asthma registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020 Aug 14;20(1):212. doi: 10.1186/s12874-020-01065-0.
PMID: 32819285BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Honorary Clinical Professor
Study Record Dates
First Submitted
March 28, 2026
First Posted
April 13, 2026
Study Start
November 1, 2025
Primary Completion (Estimated)
December 31, 2035
Study Completion (Estimated)
December 31, 2036
Last Updated
April 13, 2026
Record last verified: 2026-03